Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review
详细信息 查看全文
- 作者：Annukka Vahteraa ; annukka.vahtera@pshp.fi" class="auth_mail" title="E-mail the corresponding author ; Suvi Vaarab ; Ville Pettilä ; b ; Anne Kuitunena
- 关键词：Anti-FXa ; Critical care ; LMWH ; Thromboprophylaxis ; Monitoring
- 刊名：Thrombosis Research
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：139
- 期：Complete
- 页码：10-16
- 全文大小：378 K
文摘
- •
Despite pharmacological thromboprophylaxis, usually LMWHs, the incidence of VTE is relatively high in critically ill patients
- •
The aim of this systematic review was to evaluate the reasons to monitor plasma anti-FXa levels
- •
After screening total 18 eligible studies including 1644 patients, were selected
- •
There was a wide variation in the median peak anti-FXa levels (< 0.1-0.34 IU/ml)
- •
No conclusions can be drawn on targeted anti-FXa levels in critically ill patients when using LMWH thromboprophylaxis